Skip to main content
. 2019 May 3;11:4065–4073. doi: 10.2147/CMAR.S195485

Table 1.

Baseline patient characteristics

Characteristics PA-TACE NonPA-TACE P-value
Sex, M/F 94/8 67/11 0.176
Age, years, median (range) 55 (32–82) 56 (24–78) 0.6
Child-Pugh status A/B/C 62/5/1 57/4/0 0.233
MELD score 7 (6–10) 7 (6–9) 0.813
Laboratory values, median (range)
WBC count, 109/L 5.2 (2.0–9.6) 5.5 (2.3–13.4) 0.215
Platelet count, 109/L 154 (54–319) 154 (34–367) 0.561
Hemoglobin, g/dL 135 (84–169) 142 (103–169) 0.089
Serum total bilirubin, mg/dL 11.5 (6.9–135) 13.5 (4.7–47.2) 0.784
Serum albumin, g/dL 39.6 (30.8-59.3) 40.9 (31.8-89.3) 0.074
INR 1.10 (0–3.48) 1.08 (0–1.33) 0.003*
Serum creatinine, mg/dL 67.7 (35.6–123.2) 70.4 (47.3–97.4) 0.516
Serum alpha-fetoprotein, ng/mL
<20/≥20 30/42 40/27 0.034*
Tumor burden and distribution
Unifocal/multifocal 78/24 62/16 0.63
Maximal lesion diameter (cm) 5.94±2.95 6.23±4.34 0.595

Note: *Significant difference (P<0.05).

Abbreviations: INR, international normalized ratio; PA-TACE, postoperative adjuvant TACE; MELD, Model of End-stage Liver Disease; WBC, white blood cell.